Stock Ratings / Health Care / AHCO / forecast

STLN (37) SBC (71) OMDA (56) INNV (57) ⌘ Pro Terminal →

AdaptHealth Corp. (AHCO) 12-Month Stock Forecast & Price Target Cone

$5.93 -1.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

AdaptHealth Corp. (AHCO) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $808.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AHCO)Realized 20D OHLCV Swing Band: ±9.3%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your AHCO Position Size: $10,000

Shares at $5.93: 1686.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.35

$7,336

$-2,664 (-26.6%)

12M Consensus BaseTarget $5.58

$9,410

$-590 (-5.9%)

12M Bull Case BreakoutTarget $14.10

$23,777

+$13,777 (+137.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$6	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$13	69%	B
JP MorganUS Large-Cap Research	SELL	$5	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AHCO)

✓Walkthrough of AHCO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AHCO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.77%🛡️ HOLDING TREND SUPPORT

2026-10-30O $6.00H $6.04L $5.78C $5.93VOL 2.23M

RES: $9.35SUP: $5.71SMA50: $5.88SMA200: $9.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AHCO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AHCO Butterfly Map → + Track AHCO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-6.4%/yr Implied 5Y Growth

vs. -0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AHCO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AHCO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AHCO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AHCO)

Health Care Rank #476 of 1016 ⚔️ STLN vs AHCO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AHCO vs. STLN, SBC, OMDA, INNV)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AdaptHealth Corp. (AHCO) ranks #476 by composite RQD confidence (45/100, grade D) and #386 by equity capitalization ($808.5M). Within this direct 5-issuer industry benchmark cohort, SBC leads on earnings valuation at 11.5x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with AHCO at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AHCO ACTIVE AdaptHealth Corp.	D	45/100	—	18.8%	2.2%	-1.66%	$808.5M	Benchmark Subject
STLN Starling Oncology Inc.	D-	37/100	—	—	-35.0%	+0.15%	$677.7M	/stln-vs-ahco →
SBC SBC Medical Group Holdings Incorporated	B-	71/100	11.5x	73.3%	63.1%	+4.40%	$585.2M	/sbc-vs-ahco →
OMDA Omada Health Inc.	D+	56/100	—	65.7%	-15.7%	+2.45%	$1.20B	/omda-vs-ahco →
INNV InnovAge Holding Corp.	D+	57/100	—	18.0%	-10.2%	+1.54%	$1.26B	/innv-vs-ahco →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001725255

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AdaptHealth Corp. (AHCO) reported GAAP revenue of $3.24B (-0.5% vs. FY2024 revenue of $3.26B , and +1.4% cumulative change since FY2023) , GAAP net income of -$70.8M, operating cash flow of $601.8M, and free cash flow of $219.4M (-7.0% YoY). On the balance sheet, AHCO closed FY2025 with $4.32B in total assets against $1.72B in total debt (Altman Z-Score: 0.79, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.24B	-$70.8M	$601.8M	$219.4M	$4.32B	$1.72B
FY2024 (FY)	2024-12-31	$3.26B	$90.4M	$541.8M	$235.8M	$4.49B	$1.96B
FY2023 (FY)	2023-12-31	$3.20B	-$678.9M	$480.7M	$480.7M	—	—

3. AHCO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AHCO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, AdaptHealth Corp. (NASDAQ: AHCO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $5.93 (-1.66% 1D, market cap $808.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AHCO ranks #476 in composite RQD confidence.

How does AHCO compare to STLN and SBC in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), AHCO carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 18.8%, and ROIC of 2.2%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $677.7M) and SBC (SBC Medical Group Holdings Incorporated) posts a B- grade (71/100 RQD, P/E 11.5x, ROIC 63.1%, cap $585.2M). Among the 5-stock peer group, SBC leads on earnings multiple (11.5x) while SBC leads on capital efficiency (63.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AHCO?

Per AHCO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725255), AdaptHealth Corp. generated $3.24B in revenue (-0.5% YoY), -$70.8M in net income, and $219.4M in free cash flow against $4.32B in total assets and $1.72B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AHCO trading relative to its 50-day, 200-day, and 52-week technical levels?

AHCO last traded at $5.93 (-1.66% on volume of 2,084,597 shares), positioning the stock +0.85% above its 50-day simple moving average ($5.88) and -35.47% below its 200-day simple moving average ($9.19). Across its 52-week range of $5.21 to $13.43, AHCO sits at the 8.8% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($5.38 to $6.48).

AHCO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AHCO's 12-month stock price target?

AdaptHealth Corp. (AHCO) carries a 12-month consensus base price target of $5.58 (-5.9% from $5.93), with a bull-case target of $14.1 and a bear-case floor of $4.35.